Trial · NCT00662532

Antibiotic Study for Dental Implants

NCT00662532, Phase 3, Completed, OraPharma; results first posted 2010-05-27

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Antibiotic Study for Dental Implants. Trials, record NCT00662532. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00662532

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Antibiotic Study for Dental Implants
NCT number: NCT00662532
Status: Completed
Phases: Phase 3
Enrollment: 44 participants, actual
Lead sponsor: OraPharma
Conditions: Periodontitis
Interventions: Minocycline HCl
First posted: 2008-04-21
Last updated: 2011-12-12
Results first posted: 2010-05-27

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Overall PD Reduction	Baseline to Day 180	Mean reduction of probing depth (PD) of qualified implant sites is derived by calculating the change of PD per qualified implant site (PD at baseline minus PD at post-baseline), and then averaging the site-specific PD changes per subject
Secondary	Initial PD Reduction	Baseline to Day 90	Mean reduction of probing depth (PD) of qualified implant sites is derived by calculating the change of PD per qualified implant site (PD at baseline minus PD at post-baseline), and then averaging the site-specific PD changes per subject
Secondary	BOP Percent Reduction From Baseline	at Day 90 and Day 180	Bleeding on Probing (BOP) percentage is calculated as the number of implant sites with bleeding divided by the number of implant sites per subject times 100% at each visit; reduction of BOP percentage is the BOP percentage at baseline minus the BOP percentage post-baseline

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Overall PD Reduction	Baseline to Day 180		mm	MEAN
SECONDARY	Initial PD Reduction	Baseline to Day 90		mm	MEAN
SECONDARY	BOP Percent Reduction From Baseline	at Day 90 and Day 180	ITT	Percentage of Participants	LEAST_SQUARES_MEAN

Source ClinicalTrials.gov

Results by group8

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Overall PD Reduction	Minocycline HCl		1.25	Standard Deviation 0.63	mm
Overall PD Reduction	No Intervention		0.66	Standard Deviation 0.63	mm
Initial PD Reduction	Minocycline HCl		1.02	Standard Deviation 0.63	mm
Initial PD Reduction	No Intervention		0.49	Standard Deviation 0.58	mm
BOP Percent Reduction From Baseline	Minocycline HCl	Day 90	42.17	Standard Deviation 38.27	Percentage of Participants
BOP Percent Reduction From Baseline	No Intervention	Day 90	22.53	Standard Deviation 31.36	Percentage of Participants
BOP Percent Reduction From Baseline	Minocycline HCl	Day 180	60.75	Standard Deviation 32.19	Percentage of Participants
BOP Percent Reduction From Baseline	No Intervention	Day 180	32.86	Standard Deviation 41.35	Percentage of Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Minocycline HCl	22
Overall Study	STARTED	No Intervention	22
Overall Study	COMPLETED	Minocycline HCl	22
Overall Study	COMPLETED	No Intervention	20
Overall Study	NOT COMPLETED	Minocycline HCl	0
Overall Study	NOT COMPLETED	No Intervention	2

Source ClinicalTrials.gov

Adverse events42

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Tooth Abscess	Infections and infestations	Minocycline HCl	1	22
other	Tooth Abscess	Infections and infestations	No Intervention	1	22
other	Ear Infection	Infections and infestations	Minocycline HCl	1	22
other	Ear Infection	Infections and infestations	No Intervention	0	22
other	Infection	Infections and infestations	Minocycline HCl	0	22
other	Infection	Infections and infestations	No Intervention	1	22
other	Onychomycosis	Infections and infestations	Minocycline HCl	1	22
other	Onychomycosis	Infections and infestations	No Intervention	0	22
other	Upper Respiratory Tract Infection	Infections and infestations	Minocycline HCl	0	22
other	Upper Respiratory Tract Infection	Infections and infestations	No Intervention	1	22

1 to 10 of 42Source ClinicalTrials.gov

See all 42 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Minocycline HCl
Total, all-cause mortality	No Intervention
Total, other adverse events	Minocycline HCl	6	22
Total, other adverse events	No Intervention	4	22
Total, serious adverse events	Minocycline HCl	1	22
Total, serious adverse events	No Intervention	3	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Minocycline HCl vs No Intervention: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00662532

GET https://conductscience.org/api/trials/v1/NCT00662532/events?page=2

API reference For AI assistants